Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 9/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7049682 | 0.82 | KIF11 (0.43) | KIF11ALDH1A1HSD17B10KCNH2KMT2A | |
| SCHEMBL21562153 | 0.78 | CA4 (0.46) | KIF11ALDH1A1KCNH2KMT2ACA4 | |
| SCHEMBL17173364 | 0.78 | CA4 (0.46) | KIF11ALDH1A1KCNH2KMT2ACA4 | |
| SCHEMBL7924524 | 0.77 | KIF11 (0.47) | KIF11KCNH2SLC6A4KMT2ACA4 | |
| SCHEMBL28346610 | 0.75 | KIF11 (0.44) | KIF11ALDH1A1KCNH2KMT2ACA4 | |
| SCHEMBL8784660 | 0.74 | CA4 (0.54) | KIF11KCNH2CA4LTA4H | |
| SCHEMBL774134 | 0.74 | CA4 (0.54) | KIF11KCNH2CA4LTA4H | |
| SCHEMBL7010039 | 0.73 | KMT2A (0.44) | KIF11KCNH2KMT2A | |
| SCHEMBL17928455 | 0.72 | KIF11 (0.46) | KIF11ALDH1A1HSD17B10KCNH2KMT2A | |
| Bromide SCHEMBL31164184 | 0.72 | CA4 (0.52) | KIF11KCNH2CA4LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2131848-A2 | COMPOSITIONS AND METHODS FOR POTENTIATED ACTIVITY OF BIOLOGICALY ACTIVE MOLECULES | Merck & Co., Inc. (US) | 2009-12-16 | — | — | EP | disclosed |
| EP-2104740-A2 | LIPID NANOPARTICLE BASED COMPOSITIONS AND METHODS FOR THE DELIVERY OF BIOLOGICALLY ACTIVE MOLECULES | Sirna Therapeutics, Inc. (US) | 2009-09-30 | — | — | EP | disclosed |
| WO-2008147438-A2 | LIPID NANOPARTICLE BASED COMPOSITIONS AND METHODS FOR THE DELIVERY OF BIOLOGICALLY ACTIVE MOLECULES | SIRNA THERAPEUTICS, INC. (US) | 2008-12-04 | — | — | WO | disclosed |
| WO-2008103276-A2 | COMPOSITIONS AND METHODS FOR POTENTIATED ACTIVITY OF BIOLOGICALY ACTIVE MOLECULES | MERCK & CO., INC. (US) | 2008-08-28 | — | — | WO | disclosed |
| EP-1922300-A2 | CATIONIC LIPIDS AND FORMULATED MOLECULAR COMPOSITIONS CONTAINING THEM | Sirna Therapeutics Inc. (US) | 2008-05-21 | — | — | EP | disclosed |
| WO-2007086883-A2 | CATIONIC LIPIDS AND FORMULATED MOLECULAR COMPOSITIONS CONTAINING THEM | SIRNA THERAPEUTICS, INC. (US) | 2007-08-02 | — | — | WO | disclosed |
| WO-2007086881-A2 | CATIONIC LIPIDS AND FORMULATED MOLECULAR COMPOSITIONS CONTAINING THEM | SIRNA THERAPEUTICS, INC. (US) | 2007-08-02 | — | — | WO | disclosed |